1. Home
  2. NAK vs NTLA Comparison

NAK vs NTLA Comparison

Compare NAK & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

HOLD

Current Price

$2.02

Market Cap

1.2B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.17

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAK
NTLA
Founded
1983
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
986.9M
IPO Year
2002
2016

Fundamental Metrics

Financial Performance
Metric
NAK
NTLA
Price
$2.02
$9.17
Analyst Decision
Strong Buy
Buy
Analyst Count
2
22
Target Price
$2.50
$19.83
AVG Volume (30 Days)
6.5M
3.6M
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$57,528,000.00
Revenue This Year
N/A
$1.96
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
33.52
52 Week Low
$0.51
$5.90
52 Week High
$2.98
$28.25

Technical Indicators

Market Signals
Indicator
NAK
NTLA
Relative Strength Index (RSI) 49.42 43.15
Support Level $2.01 $8.74
Resistance Level $2.44 $9.62
Average True Range (ATR) 0.15 0.47
MACD -0.01 0.24
Stochastic Oscillator 21.70 36.04

Price Performance

Historical Comparison
NAK
NTLA

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: